Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment

NCT01265940 is registered in ClinicalTrials.gov with Prof. Dr. Thomas Otto as lead sponsor.

NCT NCT01265940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01265940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment
Lead sponsor
Prof. Dr. Thomas Otto
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2011
Completion date
August 31, 2012
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial cancer of bladder after failure of platinum-containing therapy.